Golden Recursion Inc. logoGolden Recursion Inc. logo
Advanced Search
Cybrexa Therapeutics

Cybrexa Therapeutics

Cybrexa Therapeutics is a small Molecule DNA repair Inhibitors founded in 2017.

Our bold mission

We’re passionate about improving patient outcomes and saving lives by developing the next generation of cancer therapeutics that specifically target tumors and their underlying biology.

Our technology

alphalex™ is a tumor targeting platform.

Cybrexa alphalex powers new applications and combinations of existing cancer therapeutics using an elegant approach for targeted intracellular drug delivery, independent of surface antigens. Leveraging alphalex, we are passionate about discovering new ways to effectively treat cancer and meaningfully improve lives.

Timeline

May 20, 2021
Cybrexa Therapeutics appoints pharmaceutical and financial services veteran Stephen Basso as Chief Financial Officer.
March 11, 2021
Cybrexa Therapeutics raises a $25,000,000 series B round.
June 16, 2017
Cybrexa Therapeutics raises a $6,000,000 series B round from HighCape Partners.
June 2017
Cybrexa Therapeutics raises a $6,000,000 series B round from Connecticut Innovations and HighCape Partners.

Funding Rounds

Patents

Further Resources

Title
Author
Link
Type
Date

News

Title
Author
Date
Publisher
Description
Angus Liu
October 6, 2021
FierceBiotech
Yale University spinout Cybrexa Therapeutics has developed a peptide-drug conjugate that, instead of aiming for a specific antigen, targets the acidic environment of cancer cells to deliver a toxic payload. The drug improved the efficacy of checkpoint inhibitors in mouse models of cancer.
BioSpace
May 20, 2021
BioSpace
Cybrexa Therapeutics, an oncology-focused biotechnology company developing a new class of therapeutics through its alphalexTM Peptide Drug Conjugate (PDC) tumor targeting platform, today announced that it has appointed pharmaceutical and financial services veteran Stephen Basso as Chief Financial Officer.
BioSpace
May 10, 2021
BioSpace
Study to determine safety and tolerability of CBX-12 and establish recommended Phase 2 dose

References

Golden logo
By using this site, you agree to our Terms & Conditions.